Draupnir Bio
BioTech/Drugs - N/A, N/A, dk
Draupnir Bio Details
We are a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels. The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max Planck Society, Germany. Backed by a syndicate of leading European investors, in 2019 Draupnir Bio completed a Series A funding round, raising €30 million Euros with participation from Gilde Healthcare Partners, Inkef Capital, Novo Seeds and High-Tech Gründerfonds. The company is headquartered in Copenhagen, with research operations centred in Aarhus, Denmark.
Draupnir Bio Technologies
Email Providers
Outlook
Load Balancers
Apache
Other
Mobile Friendly
Hosting
Google Cloud Hosting